In a meta-analysis, FGF-21 was found to be a potential biomarker for liver steatosis and its progression to steatohepatitis, but it had low sensitivity and specificity, i.e., 0.62 and 0.78, respectively [62]. Here, FGF21 is linked to fatty liver disease.